Superficial basal cell carcinoma on face treated with 5% imiquimod cream

Indian J Dermatol Venereol Leprol. 2006 Sep-Oct;72(5):373-5. doi: 10.4103/0378-6323.27757.

Abstract

Imiquimod, an immune response modifier, is known to possess both anti-viral and anti-tumor effect. We report our experience of treating a large superficial spreading basal cell carcinoma with 5% imiquimod cream. A 65-year-old male had an asymptomatic, hyperpigmented, slowly progressive, indurated, 3 x 4 cm plaque on the left cheek for two months. Biopsy from the lesion showed features of basal cell carcinoma. The patient was treated with imiquimod 5% cream, topically three times a week for six months with complete resolution of the lesion and without any side-effects. There was no clinical or histological recurrence after three months of stopping the treatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aminoquinolines / administration & dosage*
  • Carcinoma, Basal Cell / diagnosis
  • Carcinoma, Basal Cell / drug therapy*
  • Face / pathology
  • Humans
  • Imiquimod
  • Male
  • Ointments
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / drug therapy*

Substances

  • Aminoquinolines
  • Ointments
  • Imiquimod